Amgen Announces Webcast Of 2017 First Quarter Financial Results Read more about Amgen Announces Webcast Of 2017 First Quarter Financial Results
Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES Read more about Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES
Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma Read more about Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma
Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab) Read more about Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)
Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting Read more about Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application Read more about FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application
Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Read more about Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen Awards Three Golden Tickets for LabCentral Residency Read more about Amgen Awards Three Golden Tickets for LabCentral Residency
European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases Read more about European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients Read more about Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients
